Nederlandse versie onderaan
DIAGNOSIS OF GLAUCOMA USING EYE-TRACKING TECHNOLOGY
Start-up developing diagnostic technology for glaucoma and neurodegenerative diseases raises investment
Delft, 5 November 2020 – Reperio, an UMCG spin-off company, accelerates the diagnostic process for glaucoma and neurodegenerative diseases using eye-tracking technology. Blue Sparrows is investing in the company and will support Reperio in the development path that will lead to market introduction of the technology.
Glaucoma permanently limits the visual field of patients suffering from this condition, while neurodegenerative diseases severely impact the overall quality-of-life of patients. To evaluate the severity of these conditions, patients generally have to sit still for a long time while following instructions to perform complex tasks. With the innovative technology of Reperio this process can be completed in minutes. This leads to a cost reduction. Additionally, the ease of the measurement makes it suitable to monitor patients repeatedly over time. This makes it possible to evaluate the effect of treatments, and adjust treatments when necessary.
This technology results from the Ph.D. research of Alessandro, which he will publicly defend on November 11th 2020. The investment allows Reperio to further develop the technology and create a marketable product. ‘The Blue Sparrows proved their great worth even before finalizing the investment. They immediately sharpened my business model and helped in solidify my IP position, both crucial aspects for the future of our company. The aspects that I like the most is their speed to act and laser-like focus’, says Alessandro Grillini, founder of Reperio.
‘We are convinced that Reperio will have a big impact on the diagnostic process in Ophthalmology and Neurology. This will lead to a reduction of costs and more effective treatments. We are more than impressed by the innovation capabilities of the company and we look forward to this collaboration’, says Peter Krekel, Blue Sparrow and coach of the Reperio team.
More information: www.reperio-medtech.com